Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140664

Published: 2020

Journal Articles

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Julia Stomper, Annette M. May, Tina E. Joeckel, Peter Bronsert, Martin Werner, Michael Lübbert

Blood (2019) 134 (Supplement_1): 4265.

https://doi.org/10.1182/blood-2019-128141

Published: 2019

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma — Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective 'Deutsche Studiengruppe Multiples Myelom' (DSMM) Analysis

Giulia Graziani, Georg W. Herget, Gabriele Ihorst, Henning Schäfer, Jakob Neubauer, Annette M. May, Justus Duyster, Hermann Einsele, Ralph Wäsch, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 4710.

https://doi.org/10.1182/blood.V130.Suppl_1.4710.4710

Published: 2017

Journal Articles

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Blood (2016) 128 (22): 589.

https://doi.org/10.1182/blood.V128.22.589.589

Published: 2016

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Giulia Graziani, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Georg W. Herget, MD PhD, Karl Henne, MD, Annette M. May, Justus Duyster, MD, Werner Vach, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 5979.

https://doi.org/10.1182/blood.V128.22.5979.5979

Published: 2016

Journal Articles

Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients

Julia B. Schueler, DVM, PhD, Dagmar Wider, Kerstin Klingner, Gabrielle Melanie Siegers, PhD, Annette M May, MD, Johannes M. Waldschmidt, MD, Alexander Keller, MD, Justus Duyster, MD, Ralph M. Waesch, MD, Monika Engelhardt, MD

Blood (2015) 126 (23): 3004.

https://doi.org/10.1182/blood.V126.23.3004.3004

Published: 2015

Journal Articles

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Alexander Keller, MD, Johannes M. Waldschmidt, MD, Dagmar Wider, Dorothee Jakobs, Mandy Möller, Heike Reinhardt, Milena Pantic, PhD, Olga Grishina, MD, Gabriele Ihorst, PhD, Annette M May, MD, Anna Frey, MD, Ulrike Kohlweyer, PhD, Justus Duyster, MD PhD, Manfred Jung, PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 4260.

https://doi.org/10.1182/blood.V126.23.4260.4260

Published: 2015

Journal Articles

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia

Konrad Aumann, Anna-Verena Frey, Annette M. May, Dieter Hauschke, Clemens Kreutz, Jan P. Marx, Jens Timmer, Martin Werner, Heike L. Pahl

Blood (2013) 122 (1): 93–99.

https://doi.org/10.1182/blood-2012-11-463257

Published: 2013

Includes: Supplemental data

Journal Articles

T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency

Manuella L. Gomes Ochtrop, Sigune Goldacker, Annette M. May, Marta Rizzi, Ruth Draeger, Dieter Hauschke, Claudia Stehfest, Klaus Warnatz, Heike Goebel, Katja Technau-Ihling, Martin Werner, Ulrich Salzer, Hermann Eibel, Michael Schlesier, Hans Hartmut Peter

Blood (2011) 118 (2): 309–318.

https://doi.org/10.1182/blood-2010-11-321695

Published: 2011

Includes: Supplemental data

NARROW

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma — Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective 'Deutsche Studiengruppe Multiples Myelom' (DSMM) Analysis

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia

T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only